Kconcept / Shutterstock.com
18 December 2015Pharma
CAFC’s affirmation of PTAB Merck patent ruling raises questions
The US Court of Appeals for the Federal Circuit’s affirmation of the Patent Trial and Appeal Board’s (PTAB) decision to invalidate a Merck patent used to reduce homocysteine in the human body faced criticism from a dissenting judge, who claimed the court showed too much deference to the body’s decision.
